• Home
  • »
  • About Alexion

About Alexion

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know there is a significant unmet medical need, and that people's lives depend on our work.

Alexion developed the world’s first and only terminal complement inhibitor from laboratory through regulatory approval and commercialization for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare diseases. Alexion’s premier global metabolic rare disease franchise includes two highly innovative enzyme replacement therapies for the treatment of patients with hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

We are committed to investing in ongoing research and development focused on innovative therapies with life-transforming potential. As the global leader in complement inhibition, we are strengthening and broadening our portfolio of complement inhibitors across diverse platforms to serve patients with complement-mediated disorders beyond PNH and aHUS. At the same time, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across a range of therapeutic modalities.

Alexion has over 3,000 employees worldwide and operations in place to serve patients in 50 countries.

Alexion in Europe

Several key global and regional functions for Alexion are based in Europe, including our EMEA headquarters in Switzerland and our global supply chain and quality operations in Ireland. In addition, Alexion has operations to serve patients with devastating and life-threatening rare diseases in more than 30 European countries. 

EMEA Headquarters

Alexion Pharma GmbH
Giesshübelstrasse 30
8045 Zürich, Switzerland
Ph: +41 44 457 40 00 
Fax: +41 44 457 40 01 

Visit Alexion in Europe to learn more about our operations in Europe.
For more information about Alexion globally, please visit www.alexion.com.